CBLB502 derived from Salmonella flagellin is a novel agonist of Toll-like receptor 5 (TLR5). It has been shown that CBLB502 can exert high radioprotective efficacy on mice and primates from both GI and hematopoietic syndromes during whole-body irradiation with low toxicity and immunogenicity. However, no effective system has been used to investigate the protective effect of CBLB502 against irradiation and the related mechanism in vitro. In this study, we investigated the radioprotective properties of CBLB502 in HEK293-N-T cells constitutively expressing human TLR5 and NF-κB-dependent luciferase. HEK293-N-T cells were treated with different doses of CBLB502 prior to 60 Co-γ ray irradiation. After irradiation, cell viability was real-time measured for 4 days by using the real-time cell analysis system. We found that CBLB502 was capable of efficiently maintaining the survival rate of irradiated HEK293-N-T cells. Then apoptotic cell death and cell cycle were detected by flow cytometry. The results showed that CBLB502 pre-treatment could reduce the apoptosis and promote the recovery of irradiated HEK293-N-T cells from G2-phase arrest in a dose-dependent manner. Our data indicated that CBLB502 has a direct radioprotective effect in vitro via anti-apoptosis and promotes cell cycle recovery. The method developed here could be an effective in vitro system to screen other TLR5-target radioprotectants like CBLB502.
Introduction
With the increasing nuclear technology applications and ever growing terrorist activities, there are higher risks for military, civilian, and emergency responders to be exposed to potential lethal doses of ionizing radiation (IR). Until now, a number of compounds with diverse chemical structures and functions have been explored as medical radiation countermeasures, however, to this date none has been approved by the Food and Drug Administration for general use in humans for the prevention or treatment of acute radiation syndrome [1] . The development of new radioprotectants, not only for the biodefense against lethal doses of IR, but also for protecting patients from side effects of radiotherapy in clinic, has generated great interests.
Toll-like receptors (TLRs) are a family of type I transmembrane receptors which play a key role in the recognition of pathogen-associated molecular pattern and innate immune responses [2] . Since the discovery of TLRs, researchers have been focusing on the studies about the activity of agonists and antagonists of TLRs for the development of new generation of drugs and vaccines [3] [4] [5] . TLR5 can recognize bacterial flagellin, the major structural protein of flagellar filament, and then activate the innate immune response via NF-κB signaling [6] . CBLB502, a pharmacologically optimized polypeptide drug derived from Salmonella flagellin (a natural ligand and agonist of TLR5), which only contains the complete N and C-terminal domains of the parental protein separated by a flexible linker, entirely retains the NF-κB inducing activity of flagellin [7] . CBLB502 is an agonist of TLR5 and has shown radioprotective activity in various in vivo experiments. It can effectively protect rodents and primates from acute radiation injuries resulting from whole-body or local irradiation. Administration of a single dose of CBLB502 (0.2 mg/kg) prior to whole-body γ-ray irradiation (10 and 13 Gy) successfully protected mice from both gastrointestinal and hematopoietic radiation syndrome [7, 8] . CBLB502 could also save mice from dermatitis and oral mucositis caused by local radiation (10, 15, 20, or 25 Gy) [9] . In addition, Wang et al. [10] suggested that CBLB502 was able to protect mice from radiation pneumonitis and pulmonary fibrosis, and Li et al. [11] reported more recently that CBLB502 has antioxidative effect and scavenges free radicals in vitro. However, there was no report about an in vitro system to test and also screen the radioprotective effect of CBLB502 or other reagents. The pharmacologic function of CBLB502 is based on its binding to TLR5 on targeted cells and subsequent activation of NF-κB signaling pathway [7, 12] . NF-κB signaling drives the expression of various genes, such as Cyclin D1, c-IAP-1, and c-IAP-2 that can regulate cell proliferation, cell cycle checkpoint and apoptosis [13, 14] .
In this study, the radioprotective effects of CBLB502 on cell proliferation, apoptosis, and cell cycle regulation were evaluated using a new in vitro system, which may also be adopted for screening the TLR5-targeted radioprotectants in the future. This is the first report that directly shows the radioprotective functions of CBLB502 in vitro.
Materials and Methods
Cell culture and irradiation HEK293 cells were purchased from the Cell Culture Center, Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences (Beijing, China). For routine culture, Dulbecco's modified Eagle's medium (DMEM) with high glucose concentration (Gibco, Grand Island, USA) was used, and the cells were cultivated in complete culture medium at 37°C under 5% CO 2 atmosphere in an incubator (Thermo, Marietta, USA). The complete culture medium consisted of DMEM containing 10% heat-inactivated fetal calf serum (Gibco) and 100 U/ml penicillin/streptomycin (Gibco). Cells were trypsinized before plating or harvest.
Irradiation was carried out when the cells reached 80% confluence. First, cells of each group (irradiated and non-irradiated groups) were trypsinized, centrifuged, and resuspended in fresh culture medium, then transferred to different sterile tubes, respectively. Thereafter, irradiation was performed by 60 Co-γ ray irradiation facility with a dose rate of 15 Gy/h. After irradiation, all cells were re-plated upon the requirements of different experiments.
Expression and purification of CBLB502
The amino acid sequence of CBLB502 protein was constructed according to Burdelya's description [7] . The gene encoding CBLB502 (residues 1-296) was cloned into a modified pCold-sumo vector (pCold-SUMOb) that contains an N-terminal His6 tag, Smt3 Fusion Protein and SUMO Protease 1 cleavage site. The CBLB502 gene was synthesized by Genscript (Piscataway, USA) and amplified by PCR. PCR products were ligated into pCold-SUMOb vector via seamless cloning technique. The resultant ligation products were transformed into Escherichia coli strain DH5α and plated on LB medium containing 100 μg/ml ampicillin. The sequence of the insert in the clones was verified by DNA sequencing. CBLB502 was expressed in E. coli strain BL21(DE3). The cells were grown at 37°C in LB medium containing 100 μg/ml ampicillin. Protein expression was induced using 0.2 mM IPTG when the OD600 (optical density at 600 nm) reached 0.5. The cells were allowed to grow for 24 h at 15°C and were then collected by centrifugation. Cell pellets from a 1000 ml culture were resuspended in 40 ml lysis buffer consisting of 50 mM Tris-HCl, pH 8.0, 400 mM NaCl, and 400 μl protease inhibitor cocktail (Thermo, Rockford, USA) for subsequent sonication. The lysate was then cleared by centrifugation and the supernatant was incubated with 5 ml Ni-NTA agarose resin (Thermo) in the presence of 10 mM imidazole. The mixture was applied onto a Pierce™ disposable column (Thermo) and unbound protein was removed with washing buffer (50 mM Tris-HCl, pH 8.0, 400 mM NaCl, and 10 mM imidazole). Bound protein was eluted with elution buffer (50 mM Tris-HCl, pH 8.0, 400 mM NaCl, and 250 mM imidazole). The eluted protein was digested with SUMO Protease (Thermo) at 30°C for 1 h to cleave the N-terminal His6 tag and Smt3 Fusion Protein. His6 tag fragments were removed by Ni-NTA agarose resin and the resultant protein fractions were further purified by size-exclusion chromatography in 1× PBS buffer on Superdex 200 (16/60) using AKTA-FPLC (GE, Uppsala, Sweden). Trace amounts of endotoxin were removed from the purified protein using endotoxin removal spin columns (Thermo) according to the manufacturer's protocol. Protein concentrations were determined using the bicinchoninic acid (BCA) protein assay kit (Thermo).
Generation of NF-κB-dependent luciferase reporter cells and luciferase assay NF-κB-dependent luciferase reporter cells, which constitutively express human TLR5 and produce NF-κB-dependent luciferase in response to exogenously added flagellin, were generated by lentiviral transfection of HEK293 cells (named HEK293-N-T) as previously described [15, 16] . For luciferase assay, 10,000 reporter cells were seeded in each well of a 96-well white clear-bottom plate (Corning Co., Corning, USA) and the plate was incubated overnight. Purified CBLB502, flagellin (positive control) (Sigma, St Louis, USA) and BSA (negative control) were serially diluted, and added into wells. After 8 h of stimulation, luciferase activity was measured with Renilla-Glo luciferase assay system (Promega, Madison, USA) using a microplate reader (PerkinElmer, Hamburg, Germany).
Western blot analysis
HEK293-N-T cells were washed with PBS and lysed with extraction buffer (Cell lysis buffer; Cell Signaling, Beverly, USA), along with a protease inhibitor cocktail. Cellular debris was removed by centrifugation at 20,000 g for 20 min at 4°C. The protein concentration in supernatant was determined by BCA reagent. THP1 (human acute monocytic leukemia cell line) whole cell lysate (NOVUS, Littleton, USA) was used as a positive control for TLR5. Equal amounts of proteins (50 μg) were subject to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a polyvinylidene difluoride membrane (Millipore, Bedford, USA). The membrane was then blocked with 5% skim milk in Tris-buffered saline with 0.2% Tween-20 (TBST) and then washed three times with 0.2% TBST (10 min each). The membrane was incubated overnight with rabbit anti-human TLR5 polyclonal antibody (Santa Cruz, Dallas, USA) at 4°C. Subsequently, the membrane was washed three times with 0.2% TBST (10 min each), followed by incubation with horseradish peroxidase-conjugated anti-rabbit IgG antibody for 30 min. The protein bands were visualized by using a chemiluminescence kit (Bio-Rad, Hercules, USA).
Cell viability assay
Cell viability was measured with the xCELLigence ® Real-Time Cell Analysis (RTCA) System (ACEA, San Diego, USA) and Cell Counting Kit-8 (CCK-8) (DOJINDO, Tokyo, Japan). HEK293-N-T cells were treated with different doses of CBLB502 (0, 0.8, 4, 20, and 100 ng/ml, respectively) at 6 h prior to 16 Gy radiation. After irradiation, an aliquot of 50 μl fresh complete culture medium was added to each well of E-plate (ACEA) to detect the base line, and then 5000 irradiated cells were seeded in 100 μl fresh complete culture medium per well and were real-time observed for 4 days. Normal cells without any treatment were used as a control. To determine the effect of CBLB502 on the viability of normal cells, 5000 HEK293-N-T cells were seeded in each well of an E-plate and incubated under culture condition. After 20 h, the cells were treated with CBLB502 at final concentration of 100 ng/ml and continuously monitored for up to 96 h. Data were collected automatically every 15 min by RTCA for the duration of the experiment, and were presented in the form of a unit-less variable termed Cell Index (CI) [17] . The EC 50 values of RTCA assay representing the concentration of CBLB502 that could prevent 50% reduction of CI induced by IR were obtained directly from the dose response curves as previously described [18] . For CCK assay, 5000 irradiated cells in 100 μl medium were seeded in a 96-well plate. CCK-8 reagent was then added (10 μl/well) at different time points (24, 48, 72, 96, 120 , and 144 h, respectively) and incubated at 37°C for 2 h. Then the absorbance at 450 nm was measured with the microplate reader. Normal cells without any treatment and CBLB502-treated cells without irradiation were used as controls. Cell viability was represented as the percentage of survival cells compared to untreated (control) cells. All experiments were performed in triplicate.
Apoptotic cell death analysis
Apoptotic cell death was quantitatively determined by flow cytometry using PE-Annexin V/7-aminoactinomycin D (7-AAD) assay kit and PE-Active Caspase-3 Apoptosis Kit (BD Bioscience-Pharmingen, San Diego, USA). HEK293-N-T cells were treated with CBLB502 (4, 20, and 100 ng/ml, respectively) 24 h prior to 16 Gy irradiation, and harvested and washed with cold PBS at 24, 48, and 96 h, respectively. Normal cells and CBLB502-treated cells without irradiation were used as the controls.
For PE-Annexin V/7-aminoactinomycin D (7-AAD) assay, 1 × 10 5 cells were resuspended in 100 μl binding buffer and stained with 5 μl PE-conjugated Annexin V and 5 μl 7-AAD for 15 min in the dark. After that, 400 μl binding buffer was added to the mixture, and then the cells were analyzed using NovoCyte TM flow cytometer (ACEA) with BL2 channel (for Annexin V) and BL6 channel (for 7-AAD). For PE-Active Caspase-3 assay, 1 × 10 6 cells were resuspended in 0.5 ml Cytofix/Cytoperm™ solution and incubated on ice for 20 min for fixation and permeabilization. Subsequently, the cells were washed twice with Perm/Wash™ buffer (1×) at room temperature and resuspended in the Perm/Wash™ buffer (1×) plus antibody, and then incubated for 30 min at room temperature. Finally, cells were washed with 1 ml Perm/Wash™ buffer (1×), resuspended in 0.5 ml Perm/Wash™ buffer (1×), and then analyzed using NovoCyteTM flow cytometer with BL2 channel. For each sample, 10,000 events were recorded and the results were analyzed using NovoExpress v1.2.1 software (ACEA).
Cell cycle analysis
The effect of CBLB502 on the cell cycle was detected by flow cytometry. This assay was based on quantitative analysis of DNA content in cultured cells using the nucleic acid stain propidium iodide (PI). HEK293-N-T cells were grown at an initial concentration of 5 × 10 5 cells/ml in T-25 flasks. At about 60% confluence, the cells were treated with CBLB502 (4, 20, and 100 ng/ml, respectively) 24 h before 16 Gy irradiation, then the cells were harvested at 24, 48, 72, and 96 h after irradiation by centrifugation at 500 g for 5 min. Normal cells and CBLB502-treated cells without irradiation were used as the controls. Subsequently, the cells were fixed gently with ice-cold 70% ethanol and incubated overnight at 4°C. Then, the cells were spun down and washed twice with PBS. Finally, the cell pellets were stained in PBS buffer containing 1 mg/ml PI and 110,000 U/ml RNase A for 15 min. The stained cells were analyzed using NovoCyte TM flow cytometer. Fluorescence of PI was collected in the BL4 channel using 488 nm laser for excitation. The percentage of cells in G1, S, and G2/M phases were assessed using the NovoExpress v1.2.1 software. In each experiment, 10,000 events per sample were recorded.
Statistical analysis
Data were presented as the mean ± SEM (standard error of mean). The statistical differences between the CBLB502-treated and untreated groups were determined using independent-sample t-test, and One-way analysis of variance (ANOVA) was also used for multiple comparisons, where P < 0.05 was regarded as statistically significant. All analyses were performed using SPSS 19.0.
Results
An in vitro system to test the radioprotective effect of CBLB502
The expression and purification of CBLB502 were described in a previous report [7] with minor modifications. Purified CBLB502 (>90% purity by SDS-PAGE; Fig. 1A ) in aliquots was firstly frozen in liquid nitrogen (2 mg/ml in PBS, pH 7.4) and then stored at −80°C.
To study the protective effect of CBLB502 on the proliferation of irradiated cells, HEK293-N-T cells that express human TLR5 and NF-κB luciferase were generated. Then HEK293-N-T cells were identified by western blot analysis and luciferase assay. Western blot analysis of the lysate of the HEK293-N-T cells revealed a single band at 110 kDa (Fig. 1B) as expected for TLR5. For the luciferase assay, HEK293-N-T cells were incubated with increasing concentrations of CBLB502 to evaluate its capacity to activate NF-κB signaling. As shown in Fig. 1C , the NF-κB signaling has already been activated when HEK293-N-T cells were treated with 0.8 ng/ml CBLB502, and the signaling strength reached maximum at the concentration of about 20-100 ng/ml of CBLB502, indicating that HEK293-N-T cells could express TLR5 and generate luciferase in response to CBLB502 stimulation through TLR5-NF-κB signaling pathway in a dose-dependent manner.
CBLB502 improves the viability of irradiated cells
HEK293-N-T cells were pre-treated with serial concentrations of CBLB502 (0.8, 4, 20, and 100 ng/ml) before irradiation, and then were seeded into microwells, respectively. The dynamics of cell responses to different concentrations of CBLB502 were continuously monitored using RTCA. Control wells represented the normal cell growth in the electronic microwells without irradiation. As shown in Fig. 2B , 12 h after IR exposure, irradiation induced a gradual decline in the cell survival rate. The CI value of irradiated cells without CBLB502 treatment decreased to zero at 68 h after IR exposure, which indicated that no cells adhered to the microelectrodes. Although the CI value of irradiated cells pre-treated with 0.8 ng/ml CBLB502 (a relatively low concentration) was also reduced to zero, the time of occurrence was delayed to 86 h after IR exposure. For other groups, pre-treatment with higher concentrations of CBLB502 has shown improved viability of irradiated cells in a dose-dependent manner. Moreover, there was no effect of CBLB502 on the viability of normal cells (Fig. 2A) . These curves provided real time information about the cell growth and changes in cellular status upon CBLB502 treatment with or without irradiation.
The EC 50 value was used to illustrate the effectiveness of a radioprotective compound, which was obtained by quantitatively measuring the concentration of a compound that can protect 50% cells from the reduction of cell viability caused by irradiation. According to the cell responses to serial doses of CBLB502 shown in Fig. 2B , the RTCA-based method allowed the calculation of the corresponding EC 50 value at each time point. As shown in Fig. 2C , the protection effect of CBLB502 on HEK293-N-T cells can be detected at about 12 h after irradiation, when the EC 50 was only 3.0 ng/ml. Thereafter, the EC 50 value increased gradually and finally reached a plateau of about 40 ng/ml. This result indicated that the dose of drug CBLB502, which was required to maintain the cell viability after irradiation, was increased with the observation time extended.
Additionally, the CCK-8 assay showed that pre-treatment with a high dose of CBLB502 (100 ng/ml) could significantly improve cell survival from 48 to 144 h after exposure to IR, compared to that of cells without CBLB502 pre-treatment (Fig. 2E) . Nevertheless, there was no effect of CBLB502 on the viability of nonirradiated cells (Fig. 2D) . These results were consistent with the RTCA assay data. However, lower dose of CBLB502 had protective effect only at late stage (Fig. 2E) , which was not fully consistent with the RTCA assay. This may be due to that the detection principle and data representation mode of these two methods are different, and some variations caused by the CCK-8 measurement which cannot completely reflect the cell status in the same hole in real time as the RTCA assay.
CBLB502 reduces the cell apoptosis of irradiated cells
To confirm whether the radioprotective effect of CBLB502 is attributed to the upregulated anti-apoptotic activity of HEK293-N-T cells, the phosphatidylserine externalization and caspase-3 activation, which were early events in the apoptosis process, were measured by PE-Annexin V/7-AAD and PE-active caspase-3 assays.
Treatment of HEK293-N-T cells with different concentrations of CBLB502 (4, 20, and 100 ng/ml) for 24 h prior to 16 Gy irradiation was found to reduce the apoptosis of irradiated cells. The results of PE-Annexin V/7-AAD assay demonstrated that CBLB502-treated HEK293-N-T cells had higher viability and lower apoptosis [containing both early (Annexin V + ) and late (Annexin V + /7-AAD + ) stage of apoptotic cells] at 24, 48, and 96 h after irradiation (Fig. 3A) . Moreover, as shown in Fig. 3B , compared to the irradiated cells without CBLB502 treatment, there were significant reductions on the percentage of apoptotic cells in all of CBLB502-treated groups at both 24 h (56.16% vs 47.47%, 36.65%, and 36.14%, respectively) and 48 h (59.01% vs 41.27%, 36.32%, and 36.33%, respectively) after irradiation; however, this difference only existed in 100 ng/ml CBLB502-treated group at 96 h (33.21% vs 22.33%) after irradiation. Therefore, the results suggested that low dose of CBLB502 has anti-apoptosis effect in the early stage after radiation, but high dose of CBLB502 was needed to keep this effect in the later stage. Furthermore, as shown in Fig. 3C , the percentage of active caspase-3-positive cells was significantly reduced by pre-treatment with CBLB502 before irradiation compared to the irradiated cells without CBLB502 pre-treatment at 24 and 48 h post-irradiation. Similar to the results of PE-Annexin V/7-AAD assay, this reduction of the percentage of active caspase-3-positive cells was only shown in the pre-treatment group with high dose of CBLB502 (100 ng/ml) at 96 h after irradiation. Additionally, in both assays, the cells were treated with CBLB502 but without radiation have no significant difference compared to normal cells without any treatment. Therefore, this study indicated that upregulated anti-apoptotic activity may be an underlying mechanism for the radioprotection of CBLB502 in HEK293-N-T cells. The relative viability of HEK293-N-T cells with or without CBLB502 (100 ng/ml) treatment, which was measured by CCK-8 assay. (E) HEK293-N-T cells were pre-treated with normal medium or indicated doses of CBLB502 prior to 16 Gy ionizing radiation exposure, then the irradiated cells were seeded in a 96-well plate with 5000 cells in 100 μl fresh medium per well. CCK assays were performed at 24, 48, 72, 96, 120, and 144 h after irradiation, respectively. Data are presented as the mean ± SEM of three independent experiments. *P < 0.05.
CBLB502 promotes cell cycle recovery of irradiated cells from G2-phase arrest
To study the relationship between cell cycle and the anti-radiation effect of CBLB502, HEK293-N-T cells were pre-treated with or without CBLB502 and subsequently irradiated by 16 Gy γ-ray, and then all cells were stained with PI. The percentage of cells in G1, S, and G2/M populations was calculated based on the results obtained from cell cycle analysis by FACS, respectively. As shown in Fig. 4A , about 80% of the normal cells were in G1/S phase due to their high proliferative status. However, 48 h after irradiation, all groups of irradiated cells showed a dramatic accumulation in G2 phase and a corresponding decrease in G1/S phase. There was no significant difference between CBLB502-treated and untreated groups after the cells were irradiated (Fig. 4B) . It is indicated that all irradiated cells were undergoing the G2-phase arrest after 16 Gy irradiation. However, at 96 h after irradiation, the percentage of cells in G2 phase for CBLB502-treated cells demonstrated a significant decrease (49.81%, 40.59%, and 38.88%, respectively) compared to those without CBLB502 pre-treatment (54.55%). Additionally, the percentage of G1-phase cells was increased significantly from 10.82% (irradiated cells without CBLB502 treatment) to 13.71%, 17.21%, and 21.21% in 4, 20, and 100 ng/ml CBLB502 pre-treated groups, respectively (Fig. 4A,B) . Notably, the cells treated with higher concentration of CBLB502 showed more recovery from G2-phase arrest cause by irradiation. In addition, treatment with 100 ng/ml CBLB502 showed no effect on cell cycle in normal cells at both 48 and 96 h post-irradiation. Therefore, these results suggested that CBLB502 could promote cell cycle recovery from a significant G2-phase arrest in a dose-dependent manner, and this could be one of radioprotection mechanisms for CBLB502.
Discussion
Previous reports have demonstrated the protective effects of CBLB502, a novel agonist of TLR5 from S. flagellin, against radiation-induced injury in animal models including nonhuman primates [7, 8] . It was reported that CBLB502 exerted the radioprotective effect by inducing series of cytokines in vivo via binding to TLR5 and activating the NF-κB signaling [19, 20] . In the current study, we evaluated the radioprotective effect of CBLB502 in vitro, for the reason that it is hard to find a normal human cell line which meets the following requirements: expressing TLR5, sensitive to radiation, easy to obtain and long-term culture. To facilitate the determination of the radioprotective effect of CBLB502 in vitro, we used an HEK293-N-T cell line that constitutively expresses human TLR5 and NF-κB signaling reporter in this study.
TLR signaling has been found to promote cell proliferation in a variety of cancers [21] [22] [23] . A recent study by Cho et al. [24] showed that the stimulation of TLR5 with flagellin increased the proliferation of multiple myeloma cells which acquired some apoptosis resistance. In our study, HEK293-N-T cells were pre-treated with CBLB502 prior to irradiation, and then were investigated for cell proliferation by RTCA. As shown in Fig. 2B , CBLB502 pretreatment significantly delayed the reduction of cell viability caused by irradiation in a dose-dependent manner. However, cells treated with CBLB502 did not show proliferation recovery at 4 days after the irradiation.
Radiation-induced apoptosis is considered to be one of the main mechanisms for cell death after the exposure to irradiation [25, 26] . Recently, Jones et al. [27] reported that IR-induced apoptosis was reduced in cultured intestinal epithelial cells (IEC-6) via a TLR5-dependent mechanism. Vijay-Kumar et al. [28] also demonstrated that flagellin played a dominant role in the activation of not only innate immunity but also anti-apoptotic processes in epithelial cells. In this study, the anti-apoptotic activity of CBLB502 in its radioprotective effect on HEK293-N-T cells was investigated. The results showed that the apoptosis of HEK293-N-T cells pre-treated with different doses of CBLB502 was reduced at 48 h after irradiation. However, at 96 h after irradiation, only cells pre-treatment with high dose of CBLB502 (100 ng/ml) showed this effect. It is clearly indicated that CBLB502 could protect HEK293-N-T cells from apoptosis induced by lethal dose of IR, and that higher doses of CBLB502 may provide longer protection time.
It is well known that IR can damage the DNA of cells. In response to DNA damage, cells will activate the signal to initiate repair processes and cell-cycle arrest until the damaged DNA is repaired [29] . When cells are exposed to IR, they initiate a complex response that includes the arrest of cell cycle progression in G1 and G2, apoptosis, and DNA repair. In general, the major function of G1-phase arrest may be the elimination of cells containing DNA damage, whereas G2-phase arrest following radiation has been shown to be important in protecting cells from death [30, 31] . In our results, all cells (with and without CBLB502 pre-treatment) showed a dramatic G2-phase arrest at 48 h after irradiation that may protect cells from death caused by IR. Notably, compared to the cells without CBLB502 pre-treatment, cells pre-treated with CBLB502 showed a significant recovery from G2-phase arrest at 96 h after irradiation (Fig. 4) . These results suggest that CBLB502 may promote the repair of DNA damage and cause the termination of G2 checkpoint arrest [32] . However, at 96 h after irradiation, the percentage of G2 phase in cells of all treatment groups were still much higher than that of control cells, which might explain why CBLB502 pre-treatment showed significant delay in the reduction of cell viability caused by exposure to lethal-dose irradiation, but did not show recovery of proliferation after irradiation for 4 days observed in the RTCA assay.
In conclusion, we showed that CBLB502, a novel agonist of TLR5, has radioprotective effect in vitro. CBLB502 pre-treatment can protect HEK293-N-T cells against radiation damage by inducing anti-apoptosis activity and promoting cell recovery from G2-phase arrest. Results of our study are consistent with previous in vivo studies of the radioprotective effect of CBLB502 [7, 8] . Moreover, in the present study a RTCA-based method was used for the first time to assess the radioprotective effect of CBLB502 on cell viability and cell proliferation by real-time measurements. In contrast to traditional endpoint methods, such as CCK-8 assay, RTCA has the advantages of comprehensive representation of the cellular responses for the entire duration of the experiment. Some key conditions, such as the cell number per well, radiation dosage for different kinds of cells, time of the drug pre-treatment, and drug concentrations were easily optimized through the real-time dynamic curves of cellular responses. Thus, the method developed here could be adopted for the screening and evaluation of new radioprotectants.
